Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Arc 1Sanqing’s Breakthrough

After discovering he had terminal cancer, Wei Kang used the Primary Pharmaceutical System to create a drug that cured cancer patients and brought Sanqing Pharmaceutical international attention. The arc ended with him weighing licensing offers and seeking multinational companies’ discarded drug formulas to fuel future discoveries.

  • Wei Kang learned he had late-stage liver cancer as Sanqing Pharmaceutical faced heavy losses, then activated the Primary Pharmaceutical System and extracted a cancer-inhibiting effect from a failed drug formula.
  • Wei Kang tested his new anti-cancer drug on himself, and doctors found that his cancer had sharply improved, and he arranged clinical trials with Jian Lianyun and Zhang Bo.
  • Cao Jinmei livestreamed her rapid recovery during the trial, drawing public attention to Sanqing’s drug and prompting a surge of patients and media at the hospital.
  • Wei Kang rejected Xinmei Group’s acquisition offer, raised funds for Sanqing, and announced the company’s anti-cancer and whitening products as the drug advanced through trials.
  • At Sanqing’s launch conference, Wei Kang presented results showing a 100% response and cure rate among 420 patients, defended the data against Dr. Schmitz’s challenge, and attracted partnership offers from major pharmaceutical companies.
  • Wei Kang refused to sell Sanqing or its drug formula and required potential partners to submit toxicity-tested abandoned drug formulas and side-effect data as part of their proposals.
  • Wei Kang rejected Bayer’s acquisition offer and compared licensing proposals, favoring Pfizer’s terms while deciding to negotiate for its extensive catalog of abandoned drug formulas.
Chapters 1–25 Vol. 1 Read

Ch. 1Company Bankruptcy, Late-Stage Liver Cancer

Wei Kang faced the imminent bankruptcy of his family’s pharmaceutical company while grieving his parents and learning he had late-stage liver cancer. A Pharmaceutical System bound to him and prompted him to claim a Newbie Gift Pack, leaving him with a new chance to confront his desperate circumstances.

  • Sun Chengren reported the company’s losses, debt concerns, and shareholder withdrawals, then urged Wei Kang to consider selling it to Xinmei Group.
  • Wei Kang reviewed the acquisition proposal and learned from his medical report that he had late-stage liver cancer and less than a year to live.
  • Wei Kang broke down over his parents’ deaths, the company’s collapse, and his diagnosis.
  • The Primary Pharmaceutical System activated in Wei Kang’s mind and displayed a Drug Side Effect Extraction System panel with zero points.
  • The system told Wei Kang that he was near death and prompted him to claim the Newbie Gift Pack.
Read chapter

Ch. 2First Extraction: Testing the Drug on Himself

Wei Kang used the system’s free side-effect extraction to create an anti-cancer drug from a failed bronchitis formula. With late-stage liver cancer and little time left, he took the first pill himself and planned to check the results in three days.

  • The system granted Wei Kang one free use of its Drug Side Effect Extraction Function and tripled his points earned at level one.
  • Wei Kang searched his laboratory’s failed drug formulas for a useful side effect, then chose a bronchitis drug with a tiny cancer-cell-inhibiting effect.
  • Wei Kang used the system to extract that effect and generate a new drug formula that inhibited cancer-cell growth and damaged their DNA.
  • Wei Kang prepared seven days’ worth of tablets, swallowed one himself, and waited three days before his planned hospital checkup.
Read chapter

Ch. 3Trial Drug Succeeds, Anti-Cancer Drug Debuts

Wei Kang’s follow-up tests showed that his late-stage liver cancer had improved dramatically after he took Sanqing Pharmaceutical’s New Anti-Cancer Drug. The doctors began investigating his case, and Wei Kang revealed the drug’s origins as patients clamored to join its clinical trials.

  • Li Xuemin compared Wei Kang’s new test results with those from three days earlier and was stunned by the sharp improvement in his cancer indicators and scans.
  • Li Xuemin rushed out to gather other doctors, leaving Wei Kang alone until the waiting patients crowded into the room and demanded an explanation.
  • Jian Lianyun questioned Wei Kang and concluded that his cancer had stopped spreading and was significantly improving, then recommended hospitalization and further study.
  • Wei Kang told Jian Lianyun that he owned a pharmaceutical company and had taken its newly developed anti-cancer drug himself, proposing that they work together on his treatment and the drug’s trials.
  • Wei Kang identified the drug as a clinical-stage product from Sanqing Pharmaceutical, and patients in the room and outside eagerly volunteered for Phase III trials.
Read chapter

Ch. 4Rejecting the Acquisition, Reclaiming the Shares

Wei Kang rejected New Beauty’s acquisition offer and turned the minority shareholders’ demand to withdraw their shares into a deal for his suburban apartment. He left to retrieve the property deed while Sun Chengren prepared a share transfer agreement.

  • Wei Kang refused hospitalization, returned to the company, and decided to address internal problems before moving ahead with the new drug.
  • Wei Kang overheard Old Liu, Old Wang, and Old Chen discussing the acquisition and criticizing his plans to develop a new drug.
  • Wei Kang told Sun Chengren and the three minority shareholders that he would reject New Beauty’s offer, reminding them that his seventy percent stake gave him control.
  • The minority shareholders demanded repayment for their shares, and Wei Kang offered his suburban apartment because the company had no cash.
  • Old Liu accepted the apartment in exchange for the group’s shares, and Wei Kang asked Sun Chengren to draft a transfer agreement as he went to get the property deed.
Read chapter

Ch. 5Working Together to Accelerate Clinical Trials

Wei Kang secured company shares at a low price and told Old Sun that an improved anti-cancer drug was progressing well. He arranged with Zhang Bo to accelerate the drug’s Phase II clinical trials, with the report expected within a week.

  • Wei Kang watched the former shareholders leave and considered how to prepare for their likely return once the drug succeeded.
  • Old Sun urged Wei Kang to reconsider the acquisition, but Wei Kang shared limited good news about the improved anti-cancer drug and asked him to keep it secret until Phase III.
  • Old Sun proposed delaying supplier payments, collecting overdue receivables, renewing the company’s loan, and dismissing unproductive employees to free up funds.
  • Wei Kang called Zhang Bo and asked his CRO to speed up the drug’s additional Phase II trials before moving on to Phase III.
  • Zhang Bo reviewed Wei Kang’s Phase I data and promised to begin Phase II that day and deliver a report within a week.
Read chapter

Ch. 6Astonishing Data, Hospital Follow-Up

After the anti-cancer drug’s Phase II trial showed strong results and almost no side effects, Wei Kang planned to recruit volunteers for Phase III while seeking a faster source of company income. At his follow-up, Jian Lianyun found that his cancer had improved and agreed to help recruit trial participants.

  • Zhang Bo reported that the drug quickly suppressed tumors, showed almost no side effects, and appeared ready for Phase III testing.
  • Wei Kang agreed to fund the larger trial, then considered developing a popular health product to bring the struggling company money sooner.
  • Li Xuemin called Wei Kang to arrange a follow-up, and Wei Kang went to the hospital to see Jian Lianyun instead.
  • Jian Lianyun reviewed Wei Kang’s tests and found that cancer cells in his lungs, stomach, and other areas had decreased, though liver lesions remained.
  • Wei Kang asked Jian Lianyun to recruit hospital patients for the Phase III trial, and she agreed after requesting the Phase II data.
Read chapter

Ch. 7Father and Daughter Both Shocked, Live-Streaming the Drug Trial

After seeing astonishing Phase II results for a side-effect-free anti-cancer drug, Jian Lianyun told her father about it and recruited volunteers for its Phase III trial. Cao Jinmei, a young woman with late-stage lymphoma who livestreamed her life, announced that she had joined the trial and would broadcast the process.

  • Jian Lianyun reviewed the drug’s Phase II data and called her father, a leading oncology doctor, to recommend it for a special patient in his care.
  • After initially doubting the results, Jian Lianyun’s father agreed to wait for the Phase III data and then teased her about her male friend, prompting her to end the call.
  • Jian Lianyun posted in a WeChat group that the drug needed free Phase III volunteers, and group members rushed to sign up.
  • Cao Jinmei, a twenty-year-old with late-stage diffuse large B-cell lymphoma, prepared to livestream her treatment as she had throughout her illness.
  • Cao Jinmei told her million followers that she had enrolled in the drug trial, trusted the doctors, and would livestream the entire process.
Read chapter

Ch. 8First Day of the Drug Trial Livestream

Cao Jinmei told her livestream viewers that she had joined a clinical drug trial after seeing Grandma Liu recover, and promised to document her progress. The next day, she appeared more energetic and reported feeling stronger, leaving her fans convinced that the medicine was working.

  • Cao Jinmei explained that she cried from happiness after seeing Grandma Liu, a terminal cancer patient whose health had improved during the first week of the clinical trial.
  • Cao Jinmei said she had taken her first dose and would livestream the trial, while viewers argued over whether her claims were believable and compared the drug to Xinmei Group's expensive Anti-Cancer Injection.
  • Cao Jinmei ended the livestream after asking her fans to stop arguing and promising to show them her condition each day.
  • Cao Jinmei returned the next day looking more energetic, with less yellow skin, and ate an apple on camera.
  • Cao Jinmei reported feeling stronger, enjoying the scenery on the bus, and eating a large bowl of rice, prompting viewers to praise the medicine.
Read chapter

Ch. 9Miracle Drug Shocks the World, Hospital Overrun

Cao Jinmei’s rapid recovery from terminal cancer drew massive attention online, and she urged cancer patients to seek the drug trial at Kun City First People's Hospital. As crowds and media overwhelmed the hospital, Director Qin confirmed that Sanqing Pharmaceutical’s New Anti-Cancer Drug was undergoing a Phase III Clinical Trial there.

  • On the third day of her livestream, Cao Jinmei appeared healthy and cried with joy before ending the stream.
  • Images of Cao Jinmei’s recovery spread across platforms, drawing viewers and cancer patients to her livestream.
  • On the fourth day, Cao Jinmei thanked Kun City First People's Hospital and urged cancer patients to join its drug trial.
  • Li Xuemin and his colleagues found crowds and media surrounding the hospital’s outpatient building.
  • Jian Lianyun told Director Qin that the visitors had come because of Sanqing Pharmaceutical’s anti-cancer drug, and Director Qin confirmed the trial to reporters.
Read chapter

Ch. 10Three Purities Makes a Name, New Beauty Catches Strays

Three Purities Pharmaceutical’s three-day anti-cancer drug drew public attention, overshadowing Xinmei Group’s launch of its expensive Akilunsi Injection. The chapter left Wu Shiji furious after learning the rival drug’s trial results were real and online users were condemning New Beauty.

  • News of Three Purities Pharmaceutical’s three-day anti-cancer drug spread, and investigators found the company was a small, unlisted firm with limited staff and resources.
  • Wu Shiji introduced Xinmei Group’s Akilunsi Injection at a press conference, where Zhang Chunmei described her recovery after treatment.
  • Wu Shiji defended the injection’s high price by citing its complex production and Xinmei’s research investment, and said it could not immediately enter medical insurance.
  • A reporter asked Wu Shiji about Three Purities Pharmaceutical’s drug, and he dismissed the claim as inconceivable while industry peers laughed.
  • Wu Shiji’s assistant confirmed the drug was undergoing a Phase III Clinical Trial in Kun City and showed him a video of its results.
  • The assistant reported that online criticism of New Beauty had surged after its promotional trending topic collided with news about Three Purities Pharmaceutical, and Wu Shiji angrily smashed his tablet.
Read chapter

Ch. 11Second Extraction, Miracle Whitening Drug

The three former Sanqing Pharmaceutical shareholders discovered that Wei Kang had exchanged their shares for a worthless apartment, then learned the company’s New Anti-Cancer Drug had gone viral. Wei Kang used his system points to extract a whitening formula and began testing it on himself before Jian Lianyun called with news of the drug’s sudden fame.

  • Old Liu, Old Chen, and Old Wang found their apartment was a run-down unfinished unit and cursed Wei Kang for deceiving them.
  • Old Liu learned Sanqing Pharmaceutical’s New Anti-Cancer Drug worked in three days and had gone viral, so the three former shareholders decided to sue Wei Kang for their shares.
  • Wei Kang checked his system and found he had 120 points, enough to extract a drug side effect.
  • Wei Kang extracted a whitening and freckle-removal formula from a discarded prescription, made an ointment, and applied it to the back of his left hand.
  • Jian Lianyun called Wei Kang and told him his drug had gone viral.
Read chapter

Ch. 12Official Announcement, New Drug Launch Conference

Wei Kang promoted Sanqing Pharmaceutical’s anti-cancer drug and announced a press conference to release its Phase III data, drawing widespread attention from the media and pharmaceutical companies. As system points surged, he arranged for more medicine to be produced for Jian Lianyun’s hospital.

  • Jian Lianyun told Wei Kang that the drug trial had attracted too many applicants and asked him to send more medicine on a regular schedule.
  • Wei Kang verified his Langbo account as Sanqing Pharmaceutical’s chief executive and announced the drug’s successful Phase III trial and pending market approval.
  • Wei Kang announced a press conference for the following month and promoted the company’s new whitening product, prompting netizens to praise Sanqing Pharmaceutical and criticize Xinmei Group.
  • Media outlets and pharmaceutical companies around the world focused on Sanqing Pharmaceutical and awaited the Phase III data.
  • Wei Kang watched system points rise, then called Zhao Xiaojie to buy more raw materials and increase production for the hospital.
Read chapter

Ch. 13President Wei's Sweet, Tempting Promise

Wei Kang motivated Three Purities’ employees with promises of success, then adjusted his Whitening Drug formula and asked Zhang Bo to arrange a Phase II trial. At Oulaiya, Sheng Changya noticed Wei Kang’s announcement about the whitening and freckle-removal formula and became interested.

  • Zhao Xiaojie accepted Wei Kang’s routine raw-material orders after Wei promised that Three Purities would become a global pharmaceutical giant.
  • Wei Kang praised the rookie researchers, promised bonuses, and promoted Li Zhong to R&D team leader.
  • Wei Kang noticed that the Whitening Cream had quickly lightened his left hand, so he reduced the formula’s active ingredient concentration.
  • Wei Kang asked Zhang Bo to conduct a Phase II clinical trial for the whitening medicine and requested a report by the end of the month.
  • Sheng Changya spotted Wei Kang’s announcement about a whitening and freckle-removal drug formula while browsing Langbo and became interested.
Read chapter

Ch. 14Sheng Changya's Surprise

Sheng Changya, an Oulaiya Group product manager, contacted Wei Kang about Sanqing Pharmaceutical’s Whitening Drug after seeing a dramatic before-and-after photo. After applying a sample to a few dark spots, she woke to find her complexion clear and even, leaving her astonished by the drug’s effect.

  • Sheng Changya researched Sanqing Pharmaceutical and the New Anti-Cancer Drug, then emailed Wei Kang to request information about his Whitening and Spot-Removing Drug.
  • Wei Kang sent Sheng Changya a comparison photo showing a striking difference between the skin on his hands, and she asked to discuss the drug’s data on WeChat.
  • Wei Kang told Sheng Changya that the improved formula was undergoing Phase II trials and offered to send her a sample to test.
  • Wei Kang sent Sheng Changya about ten grams of undiluted ointment, which she reluctantly applied to several dark spots on her face.
  • The next morning, Sheng Changya saw that her face was clear, even-toned, and free of spots, and she realized the ointment had worked overnight.
Read chapter

Ch. 15The Phase III Clinical Report Was Finally Out

Sheng Changya decided to fight for a deal with Wei Kang after seeing the Whitening Drug’s dramatic results, while Wei Kang reviewed its Phase III report and received promising initial data for the anti-cancer drug. He and Sun Chengren prepared a press conference for the beginning of the next month, and anticipation for the clinical reports grew.

  • Sheng Changya praised the Whitening Drug’s overnight effect to Wei Kang and asked whether he wanted to sell the formula or cooperate with Oulaiya.
  • Wei Kang told Sheng Changya that the deal would depend on Oulaiya’s sincerity and warned that other bidders might compete once the trial data was released.
  • Sheng Changya resolved to do everything she could to secure the deal and make the product a major career achievement.
  • Wei Kang reviewed the Whitening Drug’s clinical report, which showed strong results, excellent tolerability, and no reported allergic reactions among test subjects.
  • Wei Kang received initial Phase III data showing that most of around one hundred cancer patients had been cured within a month, while the hospital’s larger trial continued.
  • Wei Kang and Sun Chengren scheduled a new drug launch conference for the beginning of the next month, and news of the event spread.
Read chapter

Ch. 16International Giants Gather, General Manager Wu is Shocked

Xinmei Pharmaceutical Chairman Wu Shiji signed a cardiovascular drug licensing agreement with Pfizer and learned that Pfizer's Asia-Pacific president, Andre, planned to attend Sanqing Pharmaceutical's press conference for its new broad-spectrum anti-cancer drug. At Sanqing's crowded press conference, Wu saw representatives of major international pharmaceutical companies and drug authorities gather, leaving him eager to see whether the drug would live up to its claims.

  • Wu Shiji signed a cardiovascular medicine licensing agreement with Andre and discussed possible anti-cancer drug cooperation with Pfizer.
  • Andre told Wu he was going to Kun City to attend Sanqing Pharmaceutical's press conference, prompting Wu to suspect that other pharmaceutical giants were interested too.
  • Wu and Andre arrived at Sanqing's headquarters the next morning and were welcomed by Sun Chengren.
  • Andre introduced Wu to Merck's global oncology president, and Wu spotted representatives from Roche and Kun City's drug administration among the attendees.
  • The crowded venue fell silent as Sanqing's press conference for its new anti-cancer drug began.
Read chapter

Ch. 17Universal Doubt, Is This Data Really Not Faked?

Wei Kang presented Sanqing Pharmaceutical’s Phase III results for its broad-spectrum anti-cancer drug, claiming a 100% cure rate and no serious side effects. The press conference grew tense when Merck’s Dr. Schmitz challenged him to say whether the data was real or fake.

  • Wei Kang opened Sanqing Pharmaceutical’s drug launch and explained how the new treatment was supposed to work.
  • Wei Kang presented clinical trial data showing a 100% response rate among 420 patients, a 100% cure rate within a month, and no serious adverse reactions so far.
  • The audience erupted in disbelief and accused Sanqing Pharmaceutical of faking the results, so Wei Kang had staff distribute the clinical reports for examination.
  • Wei Kang answered routine questions from reporters while waiting for more technical challenges.
  • Dr. Schmitz, Merck’s Global President of Oncology, questioned the extraordinary claims and demanded that Wei Kang say whether the data was real or fake.
Read chapter

Ch. 18Responding to Doubts, Slapping Faces On The Spot

At Sanqing Pharmaceutical’s press conference, Wei Kang defended the New Anti-Cancer Drug’s clinical results against Dr. Schmitz’s accusations of fabricated data and implausible side effects. Wei presented patient records and hospital doctors’ testimony, leaving Schmitz silenced and the story poised to become major news.

  • Dr. Schmitz publicly challenged Wei Kang to prove that the clinical trial data were genuine, drawing anger from domestic pharmaceutical representatives and media.
  • Wei Kang questioned Merck’s record in cancer drugs and challenged Schmitz’s argument that Merck’s vast research spending proved its superiority.
  • Wei Kang showed case files from one hundred patients at Kun City First People's Hospital and invited attendees to inspect them while protecting patient privacy.
  • Several doctors from Kun City First People's Hospital stood and vouched for the case files’ authenticity.
  • When Schmitz objected to the drug’s reportedly minor side effects, Wei Kang listed Keytruda’s adverse reactions and cited Xinmei’s cancer drug as another domestic success.
  • General Manager Wu affirmed Xinmei’s research capabilities and its partnership with Pfizer, after which Schmitz sat down without replying and reporters recognized the confrontation as major news.
Read chapter

Ch. 19Pfizer Seeks Cooperation, Announces Whitening Drug

Wei Kang announced Sanqing Pharmaceutical’s whitening and spot-removing drug after presenting evidence for its New Anti-Cancer Drug. Pfizer’s interest in cooperation triggered a rush of pharmaceutical companies seeking partnerships, and the press conference ended with Wei Kang inviting everyone to dinner.

  • Wei Kang presented patient cases that confirmed the New Anti-Cancer Drug’s effects and announced Sanqing Pharmaceutical’s whitening and spot-removing drug.
  • Pharmaceutical representatives dismissed the whitening drug, while media reporters showed enthusiasm and questioned Wei Kang about Sanqing’s plans.
  • Dr. Andre of Pfizer Inc. asked Wei Kang to discuss a partnership for the New Anti-Cancer Drug.
  • President Li of Haishi Taiji Pharmaceutical and representatives from other companies offered to cooperate with Sanqing.
  • Schmitz of Merck and the Roche Pharmaceuticals representative left as Wei Kang ended the press conference and invited the attendees to dinner.
Read chapter

Ch. 20A Perfect Ending, Director Xie's Appreciation

After Sanqing Pharmaceutical’s successful anti-cancer drug launch, Wei Kang received praise from Director Xie and celebrated with industry representatives. At the banquet, he began addressing the international companies about cooperation, leaving them waiting to hear what he would reveal.

  • Wei Kang considered how international pharmaceutical companies might help Sanqing Pharmaceutical enter overseas markets.
  • Sun Chengren directed reporters to the meal and handed them travel allowances as the guests departed.
  • Director Xie praised Wei Kang’s launch conference and promised continued support for Sanqing Pharmaceutical’s clinical trials and future work.
  • Wei Kang searched for Dr. Jian, who had defended him at the conference, but could not find her.
  • Wei Kang and Sun Chengren arrived at the banquet, where Wei Kang toasted the attendees and Andre switched from Maotai to Sprite.
  • After several rounds of drinks, Wei Kang tapped his glass and began telling the representatives that he had something to announce before discussing cooperation.
Read chapter

Ch. 21Are You Crazy? You Want to Discard the Prescription?

Wei Kang rejected any sale of Sanqing Pharmaceutical or its anti-cancer drug formula and invited companies to submit cooperation proposals. He also demanded that they provide abandoned drug formulas, a request the executives dismissed while Wei Kang secretly planned to use them to develop more medicines.

  • Wei Kang told the pharmaceutical representatives that Sanqing would not sell its formula or company and asked them to submit Chinese and English cooperation proposals.
  • The domestic companies agreed to compete for a partnership, while foreign pharmaceutical representatives reluctantly accepted Wei Kang's bidding process.
  • Wei Kang asked the companies to include abandoned, toxicity-tested drug formulas and detailed side-effect data as a mandatory condition for cooperation.
  • General Manager Wu choked on his wine, then privately concluded Wei Kang was foolish and Sanqing would never develop another successful drug.
  • Wei Kang recognized the executives' contempt and was pleased because he planned to use their discarded formulas with his system.
Read chapter

Ch. 22Multinational Giants React to the News

After Wei Kang announced Sanqing Pharmaceutical’s cooperation terms, multinational drug companies rushed to secure its Broad-Spectrum Anti-Cancer Drug ahead of the bidding conference in Kun City. As the companies prepared their offers, Sun Chengren celebrated Sanqing’s success but worried that collecting discarded formulas would waste scarce funds.

  • Dr. Andre judged Sanqing’s terms favorable to Pfizer and sent the clinical trial reports to headquarters to pursue an exclusive deal.
  • Wei Kang announced that Sanqing Pharmaceutical would hold a bidding conference in Kun City one week later, then hosted the guests at a banquet.
  • Johnson & Johnson’s chairman called an emergency meeting and ordered the company to seek an exclusive agreement for the drug.
  • Bayer AG directors reviewed the trial materials and sent Dr. Muller to Kun City with authority to negotiate, while other leading pharmaceutical companies dispatched representatives.
  • Wei Kang returned to the company with Sun Chengren, who celebrated outmaneuvering General Manager Wu but questioned whether collecting discarded drug formulas was wasteful.
Read chapter

Ch. 23President Wei's Persona, Mysterious Patient

Wei Kang hid the system’s secret by portraying himself as a superstitious collector of discarded formulas, then thanked Dr. Jian for her hospital’s help with his new anti-cancer drug. Jian Lianyun and her father discussed treating an elderly patient after the drug’s upcoming bidding conference, and she agreed to assist with the surgery.

  • Wei Kang convinced Sun Chengren that his luck and his parents’ blessings drove his drug development, keeping the system and his reasons for collecting formulas secret.
  • Wei Kang called Jian Lianyun to thank her and invite her department to dinner, but she urged him to focus on developing life-saving medicines instead.
  • Jian Lianyun praised Wei Kang as a pharmaceutical genius, and he ended the call when she continued encouraging him.
  • Jian Lianyun called her father, Jian Guohua, to discuss the Phase III results for the New Anti-Cancer Drug and an eighty-year-old patient with cancer.
  • Jian Guohua decided to wait until the bidding conference and cooperation agreement were finalized before informing the patient, then invited Jian Lianyun to assist with the surgery, and she agreed.
Read chapter

Ch. 24Choosing a Cooperation Plan

Wei Kang weighed Sanqing Pharmaceutical’s cooperation options for taking its anti-cancer drug overseas and ruled out selling the company or surrendering equity. He favored licensing with a multinational partner, but had not yet chosen among Pfizer, Bayer, and Johnson & Johnson.

  • Wei Kang and Sun Chengren discussed the need for overseas sales channels and reviewed the proposals pharmaceutical companies had submitted.
  • Wei Kang rejected Bayer’s 10-billion-euro acquisition offer, explaining that he wanted to build Sanqing rather than sell it.
  • Wei Kang compared equity investment, overseas agency rights, and licensing, concluding that licensing was Sanqing’s most practical current option.
  • Wei Kang decided to negotiate with multinational giants for the best licensing terms and consider buying domestic companies’ abandoned drug formulas.
  • Wei Kang picked up the proposals from Pfizer, Bayer, and Johnson & Johnson, leaving the final choice dependent on their sincerity.
Read chapter

Ch. 25The List of Discarded Prescriptions That Moved President Wei

Wei Kang compared Pfizer and Johnson & Johnson’s licensing proposals for Sanqing’s Broad-Spectrum Anti-Cancer Drug and decided Pfizer offered the better partnership for Sanqing’s global ambitions. Pfizer’s extensive catalog of abandoned drug formulas especially won him over, and he prepared to negotiate for the entire collection.

  • Wei Kang reviewed the licensing proposals and concluded Bayer wanted to buy out the drug formula, while Pfizer and Johnson & Johnson sought the drug for different strategic reasons.
  • Wei Kang compared Pfizer’s and Johnson & Johnson’s payment and market terms, favoring Pfizer because it focused on licensed developed markets and allowed Sanqing to pursue others.
  • Wei Kang examined the companies’ lists of abandoned drug formulas and saw potential value in side effects that could point to treatments for serious diseases.
  • Wei Kang decided to negotiate for the abandoned formulas, especially Pfizer’s catalog of more than a hundred formulas gathered from its own and acquired laboratories.
Read chapter
Arc 1 of 27
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS